| |
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about the latest innovations in packaging and aseptic filling solutions that meet the complex demands of emerging therapies. Discover how to ensure product integrity, safety and efficiency. Register now. 
|
|
Today’s Big NewsJan 17, 2025 |
|
Connecting the Innovation Districts in Cincinnati, Columbus and Cleveland, the Ohio Discovery Corridor drives opportunity, innovation, and collaboration unlike anywhere else in the Midwest. Explore the corridor. 
|
|
| By Gabrielle Masson This year’s JP Morgan struck a different tone than previous years—a very pleasant one, despite higher security anxieties following the fatal shooting of UnitedHealthcare’s CEO in December. |
|
|
|
By James Waldron Notch Therapeutics is making “significant” layoffs to conserve its cash while the cell therapy biotech seeks out new partners or investors. |
By James Waldron One of the biggest stories of last year was Lykos Therapeutics’ failure to get its MDMA candidate over the finish line for post-traumatic stress disorder. But the biotech has reminded us this week that it hasn’t given up hope yet. |
By Darren Incorvaia,Zoey Becker After six years at Apellis, Chief Operating Officer Adam Townsend is saying goodbye to take on his first CEO job. The veteran exec will depart on Feb. 21 to lead a private biotech company. |
|
BioIVT offers different tiered options to quickly customize your drug metabolism and drug-drug interaction study designs, but how do you know which matches your needs and end goals? Learn More >> 
|
|
By Andrea Park,Fraiser Kansteiner,Gabrielle Masson This week on “The Top Line,” we explore the trends that defined the industry in 2024 and predict how 2025 might shake out for biopharmas big and small. |
By Fraiser Kansteiner In the phase 3b STEP UP study, an experimental 7.2-mg semaglutide dose helped patients lose more weight on average at 72 weeks compared to placebo or semaglutide 2.4 mg, which is currently the highest dose of Novo Nordisk's drug marketed under the Wegovy brand for obesity. |
By Kevin Dunleavy A government watchdog examining the FDA’s accelerated approval pathway has released a report concluding that the agency’s controversial endorsement of Biogen’s failed Alzheimer’s treatment Aduhelm was generally an outlier. But the OIG also suggested tweaks to the approval program. |
By Noah Tong Likely to be the last defining health policy act as president, the Biden administration unveiled its list of 15 drugs for the second annual round of drug price negotiations, made possible through the Inflation Reduction Act. |
By Eric Sagonowsky As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion deal for the Chinese biopharma's phase 1 T-cell engager. Later during the conference, Takeda CEO Christophe Weber laid out the company's top pipeline prospects, a group of 6 drugs that could collectively generate $20 billion at peak. Plus more. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we explore the trends that defined the industry in 2024 and predict how 2025 might shake out for biopharmas big and small. |
|
|---|
|
|
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now. 
|
|
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
